Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes
| Autor: | Juan Ambrosioni, Tomás Pumarola, Christian Manzardo, Teresa Gallart, José M. Gatell, Montserrat Tuset, David Nicolás, Xavier Claramonte, Omar Sued, José M. Miró, Fernando Agüero, Montserrat Plana |
|---|---|
| Přispěvatelé: | Universitat de Barcelona |
| Rok vydání: | 2015 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male Interleukin 2 medicine.medical_specialty Anti-HIV Agents lcsh:Medicine HIV Infections Inflammation Primary HIV infection Drug Administration Schedule Immune system Resposta immunitària Acquired immunodeficiency syndrome (AIDS) Internal medicine Drug Resistance Viral VIH (Virus) medicine Humans Immune response lcsh:Science Cell Proliferation Multidisciplinary HIV (Viruses) business.industry lcsh:R Low dose Antiretrovirals Viral Load medicine.disease Inflamació Antiretroviral agents CD4 Lymphocyte Count Treatment Outcome Immunology Interleukin-2 lcsh:Q Infeccions per VIH Female medicine.symptom business Viral load CD8 HIV infections Research Article medicine.drug |
| Zdroj: | PLoS ONE Recercat. Dipósit de la Recerca de Catalunya instname PLoS ONE, Vol 10, Iss 7, p e0131651 (2015) Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0131651 |
| Popis: | Background Interventions during primary HIV infection (PHI) can modify the clinical course during the chronic phase. The long-term effect of structured treatment interruptions (STI) followed by low doses of interleukin-2 (IL-2) in treated PHI patients is unknown. Methods Twelve PHI patients with viral load (VL) 500 cells/mm3, and CD4/CD8 ratio >1, on antiretroviral therapy (ART) initiated within the first 90 days of infection and continued for at least 12 months were included. They underwent four STI and were then allocated (week 0 of the study) to ART alone or ART plus low doses of IL-2. ART was stopped once VL 500 cells/mm3 at 48 weeks; secondary endpoints were immune activation, inflammatory markers until 48 weeks and the time before resuming ART (CD4 500 cells/mm3 without ART at 48 weeks. All other virological and immunological parameters were comparable between groups at week 0, 'final stop' and week 48. However, the proportion of CD8-CD38+ cells, tumor necrosis factor and srIL-2 were higher in the IL-2 group at 'final stop' and week 24. All these differences vanished during follow-up. At 5 years after the final stop 3 out of 6 patients in the IL-2 group and 6 out of 6 patients in the STI group have resumed ART (P = 0.19). Conclusions STI and IL-2 failed to achieve virological control after ART interruption. STI were not deleterious in long-term follow-up, an important issue for eradication and functional cure trials. Trial Registration ClinicalTrials.gov NCT02300623 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|